Toulouse Cedex 9

• Evaluation of TNF-alpha antagonists (infliximab) withdrawal in sarcoidosis Ended recruitment
  2024-516965-35-00 5 2024-10-28 Immune system disorders
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• JAK1 inhibitor treatment of inflammatory liver adenomas Ended recruitment
  2023-505278-13-00 4 2024-10-01 -women with an inflammatory HCA proven at histology and with at least
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Ended recruitment
  2023-507655-30-00 5 2024-09-27 Obesity
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• A research study to look at long-term treatment with a medicine called NNC6019-0001 for people who have heart failure due to transthyretin a … Ended recruitment
  2022-502605-15-00 4 2024-09-16 Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended recruitment
  2023-505423-31-00 5 2024-08-08 advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
• Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended recruitment
  2023-509633-39-00 7 2024-08-06 Advanced solid tumours
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas … Ended recruitment
  2023-509947-29-00 4 2024-07-18 Anemia in patients with very low, low or intermediate risk myelodyspla
• An intensive program with quadruplet induction and consolidation plus tandem autologous stem cell transplantation in Newly Diagnosed High Ri … Ended recruitment
  2023-509383-15-00 4 2024-07-05 Multiple Myeloma
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone … Ended recruitment
  2023-508310-41-00 4 2024-06-26 Multiple myeloma
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended recruitment
  2023-509026-21-00 6 2024-06-03 severe asthma
• A study to evaluate the efficacy and safety of JCAR017 in adult subjects with a type of cancer that affects B-cells, a type of white blood c … Ended recruitment
  2024-510966-18-00 4 2024-06-03 Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended recruitment
  2022-501234-37-00 7 2024-05-07 Solid Tumours
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended recruitment
  2023-505658-17-00 4 2024-04-16 Muscle-invasive Urothelial Carcinoma

Showing 529–552 of 893 trials